BeyondSpring, Inc. (BYSI)
| Market Cap | 383.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.09M |
| Shares Out | 39.14M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $9.83 |
| Previous Close | $9.80 |
| Change ($) | 0.03 |
| Change (%) | 0.26% |
| Day's Open | 9.80 |
| Day's Range | 9.67 - 10.06 |
| Day's Volume | 94,475 |
| 52-Week Range | 9.55 - 21.50 |
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone
Webinar on Thursday, March 18 th @ 10:00 a.m. ET
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...
BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smar...
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, t...
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapi...
- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer...
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -
Former Forty Seven and Roche Senior Executives to Support Partnering Efforts Former Forty Seven and Roche Senior Executives to Support Partnering Efforts
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology t...
Poster Presentation at ESMO Congress 2020 Demonstrates Plinabulin’s Early Onset Protection, with a CIN Effect Comparable to Pegfilgrastim, Plus Improved Platelet Counts and Reduced Bone Pain Poster Pres...
New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology can...
BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention o...
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer thera...
Oncology Stocks Area Trading Materially Lower The Last 2 Months
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
Gilead Acquired Forty Seven in March 2020 for $4.9 Billion Gilead Acquired Forty Seven in March 2020 for $4.9 Billion
BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster
- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -
Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ P...
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
The company announced the pricing of a public offering of common stock.
-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p
- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN -
- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone -
- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC -
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology ...
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2019 Results - Earnings Call Transcript
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer ther...
The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years The Potential for Superio...
- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years -
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-on...
No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on InvestorPl...
Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabuli...
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-onc...
Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention Plinabulin Protects Bone Marrow from Chemotherapy-Ind...
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q3 2019 Results - Earnings Call Transcript
Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negati...
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today anno...
The stock is down due to the recent share offering done at a 20% discount to market price.
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab... [Read more...]
| Industry Biotechnology | IPO Date Mar 9, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol BYSI |
Analyst Forecasts
According to 5 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 33.25, which is an increase of 238.42% from the latest price.